All In Biotech

Drug Trial Radar · NCT04456296

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment With Marketed Testosterone Products

Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 673 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

673

Actual

Start

Jun 30, 2020

Primary completion

Jul 12, 2023

Study completion Jul 12, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Testosterone is the principal androgen produced by the male testes. Male Hypogonadism is the result of inadequate production of testosterone by the Leydig cells of the testes and is reflected by total serum concentrations of testosterone of \< 300 nanograms (ng)/deciliters (dL), with no discernible diurnal pattern. The etiology of hypogonadism may be primary or secondary. The treatment of males with primary, and in some cases, secondary hypogonadism includes administration of testosterone. Testim® and Fortesta® are topical gels that when applied daily help to increase the total testosterone levels in the blood through skin absorption. Aveed® is an injectable form of testosterone treatment and participants randomized to this treatment arm will receive 3 injections over the course of 16 weeks. This study is designed to evaluate the effect on blood pressure of approved testosterone products (Testim®, Fortesta®, and Aveed®) after 16 weeks of therapy using 24-hour ambulatory blood pressure to reveal shifts in blood pressure levels.

Conditions

  • Hypogonadism
  • Hypogonadism, Male
  • Hypogonadotropic Hypogonadism

Interventions

  • Aveed Injectable ProductDrug

    Testosterone undecanoate administered by intramuscular injections.

  • FortestaDrug

    Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).

  • TestimDrug

    Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in 24-Hour Average Systolic Ambulatory Blood Pressure to End of Study (EOS)Time frame: Baseline (Day 1), EOS Visit: up to Day 107 for the Aveed Arm, and up to Day 114 for Fortesta and Testim Arms

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Endo Clinical Trial Site #8

    Birmingham, Alabama

  • Endo Clinical Trial Site #22

    Tucson, Arizona

  • Endo Clinical Trial Site #15

    North Little Rock, Arkansas

  • Endo Clinical Trial Site #32

    Bell Gardens, California

  • Endo Clinical Trial Site #33

    Canoga Park, California

  • Endo Clinical Trial Site #30

    Beverly Hills, Florida

  • Endo Clinical Trial Site #12

    Boynton Beach, Florida

  • Endo Clinical Trial Site #34

    Boynton Beach, Florida

  • Endo Clinical Trial Site #29

    Fleming Island, Florida

  • Endo Clinical Trial Site #26

    Miami, Florida

  • Endo Clinical Trial Site #2

    Miami, Florida

  • Endo Clinical Trial Site #28

    Miami, Florida

  • Endo Clinical Trial Site #10

    Miami Beach, Florida

  • Endo Clinical Trial Site #18

    Miami Gardens, Florida

  • Endo Clinical Trial Site #3

    Oviedo, Florida

  • Endo Clinical Trial Site #4

    Pembroke Pines, Florida

  • Endo Clinical Trial Site #11

    Pompano Beach, Florida

  • Endo Clinical Trial Site #23

    West Palm Beach, Florida

  • Endo Clinical Trial Site #16

    Chicago, Illinois

  • Endo Clinical Trial Site #27

    Glen Burnie, Maryland

  • Endo Clinical Trial Site #17

    Towson, Maryland

  • Endo Clinical Trial Site #35

    East Orange, New Jersey

  • Endo Clinical Trial Site #9

    Garden City, New York

  • Endo Clinical Trial Site #7

    New York, New York

  • Endo Clinical Trial Site #25

    Winston-Salem, North Carolina

  • Endo Clinical Trial Site #5

    Dayton, Ohio

  • Endo Clinical Trial Site #13

    Bala-Cynwyd, Pennsylvania

  • Endo Clinical Trial Site #19

    Houston, Texas

  • Endo Clinical Trial Site #31

    Houston, Texas

  • Endo Clinical Trial Site #20

    Houston, Texas

  • Endo Clinical Trial Site #21

    Missouri City, Texas

  • Endo Clinical Trial Site #1

    San Antonio, Texas

  • Endo Clinical Trial Site #14

    Rutland, Vermont

  • Endo Clinical Trial Site #6

    Charlottesville, Virginia

  • Endo Clinical Trial Site #24

    Virginia Beach, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.